对肝细胞癌治疗决策的值诱导工具的范围审查

Gabrielle Ritaccio1, A Sidney Barritt Iv1,2, Jamie L Conklin3

  • 1Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, 8009 Burnett Womack Bldg, CB#7584, Chapel Hill, NC, 27599-7584, USA.

BMC gastroenterology
|February 28, 2024
PubMed
概括

这次审查发现,肝细胞癌 (HCC) 患者重视生存,但可能会以更好的生活质量进行交易. 提供者在HCC治疗决策中的偏好也各不相同.